CITIUS PHARMACEUTICALS INC (CTXR) Stock Fundamental Analysis
USA - NASDAQ:CTXR - US17322U3068 - Common Stock
0.979 USD
-0.03 (-3.07%)
We assign a fundamental rating of 2 out of 10 to CTXR. CTXR was compared to 192 industry peers in the Pharmaceuticals industry. CTXR may be in some trouble as it scores bad on both profitability and health. CTXR has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CTXR has reported negative net income.
CTXR had a negative operating cash flow in the past year.
CTXR had negative earnings in each of the past 5 years.
CTXR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of CTXR (-32.47%) is comparable to the rest of the industry.
CTXR has a Return On Equity (-63.94%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.47% | ||
| ROE | -63.94% | ||
| ROIC | N/A |
ROA(3y)-32.07%
ROA(5y)-30.7%
ROE(3y)-42.32%
ROE(5y)-39.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CTXR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for CTXR has been increased compared to 1 year ago.
CTXR has less shares outstanding than it did 5 years ago.
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -3.67, we must say that CTXR is in the distress zone and has some risk of bankruptcy.
CTXR's Altman-Z score of -3.67 is in line compared to the rest of the industry. CTXR outperforms 42.19% of its industry peers.
CTXR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CTXR has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.67 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CTXR has a Current Ratio of 0.48. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.48, CTXR is not doing good in the industry: 93.75% of the companies in the same industry are doing better.
CTXR has a Quick Ratio of 0.48. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
CTXR has a worse Quick ratio (0.15) than 95.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.15 |
3. Growth
3.1 Past
The earnings per share for CTXR have decreased strongly by -71.70% in the last year.
EPS 1Y (TTM)-71.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 22.16% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.42%
EPS Next 2Y44.34%
EPS Next 3Y36.09%
EPS Next 5Y22.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CTXR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 2.67, which indicates a rather cheap valuation of CTXR.
98.96% of the companies in the same industry are more expensive than CTXR, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 34.59. CTXR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.67 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CTXR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CTXR's earnings are expected to grow with 36.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.34%
EPS Next 3Y36.09%
5. Dividend
5.1 Amount
CTXR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CTXR (11/14/2025, 8:00:00 PM)
0.979
-0.03 (-3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners5.42%
Inst Owner Change-34.9%
Ins Owners2.9%
Ins Owner Change0%
Market Cap16.65M
Revenue(TTM)N/A
Net Income(TTM)-41.56M
Analysts80
Price Target5.1 (420.94%)
Short Float %9.58%
Short Ratio1.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.87%
Min EPS beat(2)-224.81%
Max EPS beat(2)-32.93%
EPS beat(4)0
Avg EPS beat(4)-95.7%
Min EPS beat(4)-224.81%
Max EPS beat(4)-4.05%
EPS beat(8)1
Avg EPS beat(8)-102.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-64.04%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-49.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-51.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 2.67 | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.26 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.96
EYN/A
EPS(NY)0.37
Fwd EY37.51%
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS3.82
TBVpS-2.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.47% | ||
| ROE | -63.94% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.07%
ROA(5y)-30.7%
ROE(3y)-42.32%
ROE(5y)-39.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.48 | ||
| Quick Ratio | 0.15 | ||
| Altman-Z | -3.67 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y15.42%
EPS Next 2Y44.34%
EPS Next 3Y36.09%
EPS Next 5Y22.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.55%
OCF growth 3YN/A
OCF growth 5YN/A
CITIUS PHARMACEUTICALS INC / CTXR FAQ
What is the fundamental rating for CTXR stock?
ChartMill assigns a fundamental rating of 2 / 10 to CTXR.
What is the valuation status for CTXR stock?
ChartMill assigns a valuation rating of 4 / 10 to CITIUS PHARMACEUTICALS INC (CTXR). This can be considered as Fairly Valued.
Can you provide the profitability details for CITIUS PHARMACEUTICALS INC?
CITIUS PHARMACEUTICALS INC (CTXR) has a profitability rating of 1 / 10.
What is the financial health of CITIUS PHARMACEUTICALS INC (CTXR) stock?
The financial health rating of CITIUS PHARMACEUTICALS INC (CTXR) is 2 / 10.